Clinical trials in AML of the elderly: Should we change our methodology?

Leukemia

Volumn 18, Issue 11, 2004, Pages 1772-1774

  Estey, E ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORODEOXYADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HYPOCHOLESTEROLEMIC AGENT; IDARUBICIN; IMATINIB; INTERFERON; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ANALYTIC METHOD; ANALYTICAL ERROR; CANCER MORTALITY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL STUDY; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG MECHANISM; ELDERLY CARE; HUMAN; INTERMETHOD COMPARISON; LEUKEMIA REMISSION; MOLECULAR BIOLOGY; NOTE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PUBLICATION; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; SAMPLE SIZE; STATISTICAL ANALYSIS;

EID: 8844221254     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403530     Document Type: Note

References (9)

1. Schlenk RF, Fröhling F, Hartmann F, Fischer JTh, Glashmacher A, del Valle F et al. Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia 2004; 18: 1798-1803.
2. Estey E, Thall P, Pierce SS, Cortes J, Bera M, Katarjian H et al. Randomized phase II study fludarabine+cytosine arabinoside+ idarubicin±all-transretinoic acid±granulocyte colony stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 1999; 93: 2478-2484.
3. Lowenberg B, van Putten W, Theobald M, Gmür J, Verdonck L, Sonneveld P et al. For the Dutch-Belgian Hemato-Oncology Cooperative Group and the Swiss Group for Clinical Cancer Research. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. NEJM 2003; 349: 743-752.
4. Simon R. Importance of prognostic factors in cancer clinical trials. Cancer Treat Rep 1984; 68: 185-192.
5. List AF, Kopecky KJ, Willman C, Head D, Persons D, Slovak M et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 2001; 98: 3212-3220.
6. Li HY, Appelbaum FR, Willman C, Zager R, Banker D. Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood 2003; 101: 3628-3634.
7. Estey EH, Thall PF. New designs for phase 2 clinical trials. Blood 2003; 102: 442-448.
8. Thall PF, Simon RM, Estey EH. New statistical strategy for monitoring safety and efficacy in single-arm clinical trials. J Clin Oncol 1996; 14: 296-303.
9. Berry DA. Statistical innovations in cancer research. In: Kufe D, Pollock R, Weichselbaum R, Bast R, Ganster T, Holland J, Frei E (eds). Cancer Medicine, 6 edn, Chapter 33. London: BC Decker, 2003, pp 465-478.